PRIMARY STUDY
Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management
Key Findings: This review highlights the potential of phytocannabinoids as multi-target modulators of type 2 diabetes via SGLT2 and complementary metabolic pathways, showing promising preclinical and early clinical efficacy but requiring optimization of bioavailability, safety, and large-scale clinical validation to match or surpass synthetic SGLT2 inhibitors.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Indonesia
Year of Pub: 2025
Cannabinoids Studied: Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Not Applicable
Route of Administration: In vitro, Injection, Oral (Ingestion)
Citation: Tjandrawinata RR, Harbuwono DS, Soegondo S, Taslim NA, Nurkolis F. Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. Pharmaceuticals (Basel). 2025 Jul 24;18(8):1101. doi: 10.3390/ph18081101. PMID: 40872492; PMCID: PMC12389431.
